Oncolytics Biotech Inc T.ONC

Curious about Monday at ASH, nothing noted about this

[canadafan]

https://ash.confex.com/ash/2021/webprogram/Paper151575.html

This is the first glance of ONC/Pela/ Reolysen getting into Luekemia, study
Alongside BMS of all companies.
Curious why zero press on this one. Perhaps Tuesday as the presention is MOnday eve.

[Noteable]

Just for clarification - 'Reolysin' was the trade name given to ONCY's TD3 strain of reovirus for human adiministration, when Thompson was CEO, and is still used by many researchers to describe pelareorep. However, the generic name of the TD3 strain is 'pelareorep' and this generic name was granted by the FDA after this regulatory agency stated that the name 'Reolysin'

[lonc17]

Reolysin was the trade name in use for about fifiteen years.  The reason given by ONC for the change to Pelareorep has always stuck me as being completely fabricated and pure bogus nonsense.  I believe the name was changed from Reolysin to Pelareorep for strategic purposes... to help bury fifteen years worth of failed clinical trials and "re-brand" the virus as they move ever

[inthno]

Hey note, thanks for your thoughts on the name change to pela from Reolysin but that has always confused me as there are a multitude of drugs out there with the same similar name and none of them have had to change from what I know, I believe that said that it sounded too similar to bromycin, don't really think you could mix that one up and I believe that the trademark name in Europe was

[Noteable]

ONCY has better things to do other than chasing around to produce evidence of the FDA's request to refer to ONCY'S TD3v reovirus under the generic name 'pelareorep' which is the nomenclature that the FDA provided. It was an easy decision for ONCY to make. If anyone wants evidence they can do the work themselves by searcing the FDA site. Have fun.

[Noteable]

Every listed drug requires a generic name. For instance the generic name for the drug with the trade name Asprin is acetaminophen. When ONCY developed the variant of the TD3 reovirus which is known as TD3v reovirus and ONCY obtained a composition of matter patent for this variant which expires in 2028 and extendable to 2033, the variant did not have a generic name even though it now had

[Noteable]

Correction: Asprin is acetylsalicylic acid and Tylenol is acetaminophen.

[Conquistador1]

THe generic name for aspirin is acetylsalicylic acid. I haven't owned ONC for a few years. I sold it some time after they dropped the Reolysin trade mark. I agree that the trade mark carried either negative value, or they forgot to renew the trade mark which lapsed on May 31, 2018.  I doubt the FDA asked them to change it. I don't have a dog in this race but the best thing that

[canadafan]

Interesting you note you have no dog in this race, yet recommended selling @ $3ps. one needs to note  there are a handful of analysts with 12 month targets of between $6ps & $15Ps. you are 100% correct, a $3ps would not be recommended or accepted. Nor would it be offered. $10ps maybe. recall, ONC has an active partnership with China partner A.N.  That alone is worth much more

[unNoteable]

Canadafan - ONCY is worth whatever the market prices it as... After 20+ years they still do not have in vivo data credible enough to entice big pharma to invest in a Phase III. When this was $3, you were saying how this company was going to the moon, and how much it was undervalued. If anyone had taken your advice and bought in for fear of missing out, they would be on more than a 50% loss... I